Orthobiologics Market Research Report, Analysis, Size, Share, Growth by Forecast to 2026

Orthobiologics Market Overview:

The global Orthobiologics Market, valued at $5.4 billion in 2021, is expected to grow at a rate of 7% annually through 2026. This growth is driven by factors such as an increasing number of sports injuries and road accidents, a growing elderly and obese population, a rising prevalence of arthritis and spine-related disorders, patient preference for minimally invasive procedures, and advancements in biomaterials technology.

Unlock Insights for 2026 — Year-End Discounts on Premium Market Reports!

Orthobiologics involves using biomaterials and cell-based therapies to accelerate the healing of musculoskeletal injuries. These treatments are derived from naturally occurring substances in the body, which interact with the musculoskeletal system to promote the repair of bones, cartilage, ligaments, tendons, and menisci. These products are widely used in orthopedic procedures to support tissue regeneration and healing.

Technological Advancements Fueling Growth in the Orthobiologics Market

Advancements in orthobiologics have led to the development of more effective products with enhanced healing capabilities and a broader range of applications. These innovations provide a competitive edge for manufacturers, prompting ongoing investment in research and the development of new products. Key technological developments include:

• October 2022: Paragon 28 launched the V92-FC+ Cellular Bone Matrix, a moldable allograft matrix with primitive cells, designed to treat bone defects and remodeling in the foot and ankle.
• June 2022: Royal Biologics received FDA 510(k) clearance for its MAXX-BMC system, a bone marrow aspirate concentration system that enables optimal sample collection from patients during procedures.
• June 2022: Istos Biologics launched the Influx Fibrant line of 100% cortical allografts, featuring patented technology to support patient healing.
• March 2022: SeaSpine introduced NorthStar cervical facet fusion and Flash navigation lumbar facet fusion systems to improve procedural workflows and enhance fusion success rates.
• September 2020: Cerapedics’ i-FACTOR+ Matrix bone graft, approved by Health Canada, is designed to support bone growth using a P15 osteogenic peptide for cell attraction, attachment, and activation.

Key Growth Strategies by Market Leaders

Leading companies in the orthobiologics sector are adopting strategic acquisitions and partnerships to expand their product portfolios, increase market reach, and co-develop new technologies. Some notable moves include:

• October 2022: HippoFi (formerly ORHub) entered into a strategic agreement with Precision Spine to market biological solutions for spine surgery through Precision’s extensive presence in the spine market.
• August 2022: Orthofix Medical partnered with CGBio, a synthetic bone graft developer, to co-develop and commercialize bone growth solutions for the US and Canadian markets.
• July 2021: Celularity Inc. and Arthrex, Inc. formed a partnership to distribute placental-derived biomaterials for orthopedic and sports medicine applications in the US.
• April 2022: Isto Biologics acquired TheraCell, Inc., expanding its portfolio of orthopedic grafts.
• March 2021: SeaSpine Holdings Corporation acquired 7D Surgical, a Canadian medical device company, aiming to combine spinal implants with orthobiologics to improve spine surgery.

North America’s Dominance and Asia Pacific's Growth Potential

North America holds the largest share of the global orthobiologics market, driven by widespread adoption of biologics for treating bone disorders, favorable reimbursement policies, and a high incidence of arthritis and sports injuries. However, the Asia Pacific region is poised to experience the fastest growth due to an aging population, rising obesity rates, increasing prevalence of bone diseases, greater healthcare spending, and higher disposable incomes. Additionally, the growing presence of major market players in the region will further accelerate growth.

Impact of COVID-19 on the Orthobiologics Market

The COVID-19 pandemic negatively impacted the orthobiologics market, primarily due to a reduction in patient visits and disruptions to supply chains, leading to a decline in sales for some companies. For example, Orthofix Medical saw an 11% decrease in revenue in 2020 compared to 2019 but recovered in 2021 with a 14% increase in sales. Despite these challenges, demand for orthobiologics rebounded in 2021 as patient volumes increased and government restrictions eased.

Growth Prospects Despite Challenges

While challenges such as unfavorable reimbursement policies and pricing pressures remain, the orthobiologics market is expected to continue growing, particularly in the spinal fusion segment, the use of demineralized bone putties, viscosupplements, and innovations aimed at simplifying procedures. For example, the viscosupplements segment is projected to grow due to advancements in hyaluronic acid-based therapies and the rising preference for non-surgical treatments for osteoarthritis.

Additionally, conventional techniques like autografts and allografts, though effective, are complex, painful, and often require repeat surgeries. As a result, there is increasing demand for more straightforward, cost-effective solutions that are easier to manage and yield better outcomes, creating opportunities for market players.

Browse Report: https://meditechinsights.com/orthobiologics-market/

Competitive Landscape

The orthobiologics market is highly competitive, with established players such as Medtronic Plc (Ireland), Zimmer Biomet Holdings, Inc. (US), Arthrex, Inc. (US), Bioventus (US), DePuy Synthes (Johnson & Johnson Services, Inc.) (US), Stryker Corporation (US), MTF Biologics (US), and others playing significant roles in driving innovation and market expansion.

Related Report:

HPV Testing and PAP Test Market      https://www.pharmiweb.com/press-release/2025-12-18/hpv-testing-and-pap-test-market-share-size-growth-forecast-till-2030

Cellular Health Screening Market      https://www.pharmiweb.com/press-release/2025-12-18/cellular-health-screening-market-2030-analysis-size-share-growth-trends-and-forecast

Hematology Market   https://www.pharmiweb.com/press-release/2025-12-18/hematology-market-outlook-2030-industry-trends-and-competitive-analysis

Long-Term Care Software Market      https://www.pharmiweb.com/press-release/2025-12-18/long-term-care-software-market-demand-for-evidence-based-medicine-and-research-updates

About Medi-Tech Insights;

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com